Cargando…

KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review

Ampullary adenocarcinoma (A-AC) is a rare malignancy arising from the ampulla of Vater. KRAS mutation is detected in 30–40% of patients with A-AC, but its clinical implication and prognostic value are not well described. We conducted this meta-analysis to investigate the association between KRAS mut...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Bum Jun, Jang, Hyun Joo, Kim, Jung Han, Kim, Hyeong Su, Lee, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295407/
https://www.ncbi.nlm.nih.gov/pubmed/27517148
http://dx.doi.org/10.18632/oncotarget.11156
_version_ 1782505430861217792
author Kim, Bum Jun
Jang, Hyun Joo
Kim, Jung Han
Kim, Hyeong Su
Lee, Jin
author_facet Kim, Bum Jun
Jang, Hyun Joo
Kim, Jung Han
Kim, Hyeong Su
Lee, Jin
author_sort Kim, Bum Jun
collection PubMed
description Ampullary adenocarcinoma (A-AC) is a rare malignancy arising from the ampulla of Vater. KRAS mutation is detected in 30–40% of patients with A-AC, but its clinical implication and prognostic value are not well described. We conducted this meta-analysis to investigate the association between KRAS mutation and prognosis in patients with A-AC. We searched Pubmed, MEDLINE, EMBASE, and the Cochrane Library databases for articles including following terms in their titles, abstracts, or keywords: ‘ampullary or periampullary or ampulla of vater’, ‘cancer or carcinoma’, and ‘KRAS’. There were five studies with survival data of patients. A total of 388 patients with A-AC from the 5 studies were included in the overall survival (OS) analysis, and 169 patients from 2 studies were eligible for the relapse-free-survival (RFS) analysis. Out of 388 patients, 175 (45%) had KRAS mutation. There was no association between KRAS mutation and OS (HR = 1.06, 95% CI: 0.87–1.29, P = 0.58). However, there was a significant correlation between KRAS mutation and worse RFS (HR = 2.74, 95% CI: 1.52–4.92, P = 0.0008). In conclusion, this meta-analysis indicates that KRAS mutation is associated with poor RFS, but not with OS in patients with A-AC.
format Online
Article
Text
id pubmed-5295407
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-52954072017-02-08 KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review Kim, Bum Jun Jang, Hyun Joo Kim, Jung Han Kim, Hyeong Su Lee, Jin Oncotarget Research Paper Ampullary adenocarcinoma (A-AC) is a rare malignancy arising from the ampulla of Vater. KRAS mutation is detected in 30–40% of patients with A-AC, but its clinical implication and prognostic value are not well described. We conducted this meta-analysis to investigate the association between KRAS mutation and prognosis in patients with A-AC. We searched Pubmed, MEDLINE, EMBASE, and the Cochrane Library databases for articles including following terms in their titles, abstracts, or keywords: ‘ampullary or periampullary or ampulla of vater’, ‘cancer or carcinoma’, and ‘KRAS’. There were five studies with survival data of patients. A total of 388 patients with A-AC from the 5 studies were included in the overall survival (OS) analysis, and 169 patients from 2 studies were eligible for the relapse-free-survival (RFS) analysis. Out of 388 patients, 175 (45%) had KRAS mutation. There was no association between KRAS mutation and OS (HR = 1.06, 95% CI: 0.87–1.29, P = 0.58). However, there was a significant correlation between KRAS mutation and worse RFS (HR = 2.74, 95% CI: 1.52–4.92, P = 0.0008). In conclusion, this meta-analysis indicates that KRAS mutation is associated with poor RFS, but not with OS in patients with A-AC. Impact Journals LLC 2016-08-09 /pmc/articles/PMC5295407/ /pubmed/27517148 http://dx.doi.org/10.18632/oncotarget.11156 Text en Copyright: © 2016 Kim et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Kim, Bum Jun
Jang, Hyun Joo
Kim, Jung Han
Kim, Hyeong Su
Lee, Jin
KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review
title KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review
title_full KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review
title_fullStr KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review
title_full_unstemmed KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review
title_short KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review
title_sort kras mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295407/
https://www.ncbi.nlm.nih.gov/pubmed/27517148
http://dx.doi.org/10.18632/oncotarget.11156
work_keys_str_mv AT kimbumjun krasmutationasaprognosticfactorinampullaryadenocarcinomaametaanalysisandreview
AT janghyunjoo krasmutationasaprognosticfactorinampullaryadenocarcinomaametaanalysisandreview
AT kimjunghan krasmutationasaprognosticfactorinampullaryadenocarcinomaametaanalysisandreview
AT kimhyeongsu krasmutationasaprognosticfactorinampullaryadenocarcinomaametaanalysisandreview
AT leejin krasmutationasaprognosticfactorinampullaryadenocarcinomaametaanalysisandreview